ArticleFrontiers in oncology2025
Radiomics model based on vertebral calcium-suppressed CT images for predicting chemotherapy-induced myelosuppression in nasopharyngeal carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a radiomics model based on vertebral calcium-suppressed (CaSupp) images derived from dual-layer computed tomography (DLCT) for predicting chemotherapy-induced myelosuppression in patients with locally advanced nasopharyngeal carcinoma (LANPC). Methods: This retrospective study included 150 LANPC patients treated with induction chemotherapy (IC). Radiomics features were extracted from lumbar vertebral CaSupp obtained from baseline DLCT scans. Models were developed to predict myelosuppression after the first chemotherapy cycle (IC - 1) and entire chemotherapy cycles (IC-n). The clinics, radiomics, and combined models were conducted via multivariate logistic regression. Models performance was evaluated by the area under the receiver operating characteristic curve (AUC). Clinical utility was analyzed with decision curve analysis. Results: For predict myelosuppression after IC - 1, the clinics, radiomics, and combined models had AUC values of 0.716, 0.825 and 0.859 in the train cohort, respectively; and AUC of 0.687, 0.752 and 0.790 in the test cohort, respectively. And for IC-n, the clinics, radiomics, and combined models exhibited AUC values of 0.771, 0.824, and 0.889 in the train cohort, respectively; and AUC of 0.652, 0.740 and 0.806 in the test cohort, respectively. For predicting myelosuppression after both IC - 1 and IC-n,the combined models demonstrated significantly higher AUC values than the clinics models for both IC - 1 and IC-n (all P<0.05). Conclusions: Radiomics model based on vertebral CaSupp images from DLCT could predict chemotherapy-induced myelosuppression in LANPC patients. This study highlights the potential of DLCT technology to provide quantitative bone marrow assessments and aid in personalized treatment planning. External validation and comparison with other imaging modalities are warranted in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.